Lakefront Biotherapeutics (LKFT) Divestments (2021 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Divestments for 6 consecutive years, with $2.7 million the latest figure, recorded in Q1 2026.

• Quarterly Divestments fell 92.66% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.6 million (down 141.75% YoY) and the FY2025 annual result came in at $22.1 million, up 317.13% from the prior year.
• Divestments climbed to $2.7 million in Q1 2026 per LKFT's latest filing, from $1.8 million in the prior quarter.
• Over the last five years, Divestments for LKFT reached as high as $36.3 million in Q1 2025 and fell as low as -$1.1 billion in Q1 2022.
• A 5-year average of -$125.1 million and a median of -$1.5 million in 2024 frame the typical range for Divestments.
• The largest YoY upside for Divestments was 2484.24% in 2025 against a maximum downside of 473.44% in 2025.
• Year by year, Divestments stood at -$1.1 billion in 2022, then jumped by 69.08% to -$328.5 million in 2023, then soared by 100.44% to $1.4 million in 2024, then advanced by 28.73% to $1.8 million in 2025, then jumped by 44.45% to $2.7 million in 2026.
• According to Business Quant data, Divestments over the past three periods registered $2.7 million, $1.8 million, and $9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.